Clinical Trial Update: Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety and tolerability of a bioconjugate vaccine targeting Shigella flexneri 2a has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Shigellosis

Drugs mentioned

• Bioconjugate vaccine against Shigella flexneri 2a

Snippet

Sponsor: LimmaTech Biologics AG | Conditions: Shigellosis | Phase 1 | Status: COMPLETED